跳至主要内容
临床试验/EUCTR2005-002229-30-ES
EUCTR2005-002229-30-ES进行中(未招募)1 期

utropin alfa in mid follicular phase in women at risk of poor response suppresed with cetrorelix: an exploratory trial.Lutropina alfa en mitad de la fase folicular en mujeres con riesgo de pobre respuesta en supresión con cetrorelix: estudio exploratorio - Lutropin alfa in risk of poor response.

Serono España, S.A.0 个研究点目标入组 0 人开始时间: 2005年7月11日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. Pre-menopausal women, aged =38, wishing to conceive.
  • 2. Infertility justifying ICSI-TE treatment.
  • 3. At risk of poor response criteria due to previous poor response, cancellation of previous cycles or FSH levels.
  • 4. Having regular spontaneous menstrual cycle lasting 25-35 days.
  • 5. To be included under GnRH antagonist protocol.
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Known to be HIV, HBV/HCV positive.
  • 2. Any clinically significant systemic disease; tumours of the hypotalamus and pituitary gland; ovarian, uterine or mammary cancer; hormonal abnormality and/or medical, biochemical, hematological condition which in the judgement of the investigator may interfere with gonadotropin treatment.
  • 3. More than 3 previous ART cycles.
  • 4. Cryopreserved embryos from previous cycles with the same partner.

研究者

发起方
Serono España, S.A.

相似试验